GlassScriptPhysician profile
James M Houser
NPI 1821096181
$16,110.45
in general payments reported to CMS, 2019-2025
69 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,446 · 2020: $1,857 · 2021: $2,623 · 2022: $2,527 · 2023: $2,625 · 2024: $2,583 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,657.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,261.86 | 2019-2025 | Nuplazid |
| Ucb, INC. | $1,168.36 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Abbvie INC. | $1,108.61 | 2021-2025 | |
| Biogen, INC. | $1,013.88 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $899.32 | 2019-2025 | |
| Amgen INC. | $855.36 | 2019-2025 | Uplizna, Aimovig |
| Csl Behring | $571.10 | 2019-2025 | Hizentra |
| Genzyme Corporation | $495.56 | 2019-2025 | |
| Sk Life Science, INC. | $426.57 | 2020-2025 | |
| Lilly USA, LLC | $425.93 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Grifols USA, LLC | $414.44 | 2019-2025 | Gamunex-C |
| Pfizer INC. | $379.89 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $356.41 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $325.90 | 2019-2024 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $307.70 | 2019-2025 | Ultomiris, Soliris |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Houser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.